Achieve Life Sciences Inc (NASDAQ:ACHV) has coverage initiated with a Buy rating and $12.00 price target

ME Staff
-
0

Analyst Ratings For Achieve Life Sciences Inc (NASDAQ:ACHV)

Today, LADENBURG THALM/SH SH initiated coverage on Achieve Life Sciences Inc (NASDAQ:ACHV) with a Buy with a price target of $12.00.

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Achieve Life Sciences Inc (NASDAQ:ACHV) is Buy with a consensus target price of $12.00 per share, a potential 284.62% upside.

Some recent analyst ratings include

  • 8/20/2018-Achieve Life Sciences Inc (NASDAQ:ACHV) has coverage initiated with a Buy rating and $12.00 price target

Recent Insider Trading Activity For Achieve Life Sciences Inc (NASDAQ:ACHV)
Achieve Life Sciences Inc (NASDAQ:ACHV) has insider ownership of 29.00% and institutional ownership of 19.43%.

  • On 8/19/2016 John Bencich, CFO, sold 1,380 with an average share price of $0.57 per share and the total transaction amounting to $786.60.
  • On 6/13/2016 Cindy Jacobs, CMO, sold 1,437 with an average share price of $1.03 per share and the total transaction amounting to $1,480.11.
  • On 6/13/2016 Scott Daniel Cormack, CEO, sold 4,856 with an average share price of $1.03 per share and the total transaction amounting to $5,001.68.
  • On 3/15/2016 Cindy Jacobs, CMO, sold 3,254 with an average share price of $0.83 per share and the total transaction amounting to $2,700.82.
  • On 3/15/2016 John Bencich, CFO, sold 834 with an average share price of $0.83 per share and the total transaction amounting to $692.22.
  • On 3/15/2016 Scott Daniel Cormack, CEO, sold 12,033 with an average share price of $0.83 per share and the total transaction amounting to $9,987.39.
  • On 8/18/2015 John Bencich, CFO, sold 1,427 with an average share price of $2.76 per share and the total transaction amounting to $3,938.52.

About Achieve Life Sciences Inc (NASDAQ:ACHV)
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is headquartered in Bothell, Washington.

Recent Trading Activity for Achieve Life Sciences Inc (NASDAQ:ACHV)
Shares of Achieve Life Sciences Inc closed the previous trading session at 3,05 +0,25 8,93 % with shares trading hands.